Royalty Pharma plc (RPRX)
NASDAQ: RPRX · Real-Time Price · USD
37.11
+0.31 (0.84%)
At close: Aug 1, 2025, 4:00 PM
37.50
+0.39 (1.05%)
Pre-market: Aug 4, 2025, 7:00 AM EDT

Royalty Pharma Stock Forecast

Stock Price Forecast

The 4 analysts that cover Royalty Pharma stock have a consensus rating of "Strong Buy" and an average price target of $46.75, which forecasts a 25.98% increase in the stock price over the next year. The lowest target is $40 and the highest is $54.

Price Target: $46.75 (+25.98%)
Analyst Consensus: Strong Buy
TargetLowAverageMedianHigh
Price$40$46.75$51$54
Change+7.79%+25.98%+37.43%+45.51%

Analyst Ratings

The average analyst rating for Royalty Pharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

RatingFeb '25Mar '25Apr '25May '25Jun '25Jul '25
Strong Buy333333
Buy222221
Hold111110
Sell000000
Strong Sell000000
Total666664

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Citigroup
Citigroup
Strong Buy
Maintains
$40$42
Strong BuyMaintains$40$42+13.18%Jul 22, 2025
Morgan Stanley
Morgan Stanley
Buy
Maintains
$51$54
BuyMaintains$51$54+45.51%Jul 10, 2025
Citigroup
Citigroup
Strong Buy
Maintains
$60$40
Strong BuyMaintains$60$40+7.79%Oct 25, 2024
Goldman Sachs
Goldman Sachs
Strong Buy
Maintains
$50$51
Strong BuyMaintains$50$51+37.43%Aug 14, 2024
Morgan Stanley
Morgan Stanley
Buy
Maintains
$48$51
BuyMaintains$48$51+37.43%Jul 11, 2024
More Analyst Ratings

Financial Forecast

Revenue This Year
2.91B
from 2.26B
Increased by 28.60%
Revenue Next Year
3.15B
from 2.91B
Increased by 8.07%
EPS This Year
4.37
from 1.91
Increased by 128.54%
EPS Next Year
5.11
from 4.37
Increased by 16.96%
Fiscal YearFY 2020FY 2021FY 2022FY 2023FY 2024FY 2025FY 2026FY 2027
Period EndingDec 31, 2020Dec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026Dec 31, 2027
Revenue
2.12B2.29B2.24B2.35B2.26B2.91B3.15B3.42B
Revenue Growth
16.98%7.87%-2.28%5.24%-3.86%28.60%8.07%8.65%
EPS
1.321.490.102.531.914.375.115.73
EPS Growth
-12.97%-93.44%2,490.74%-24.54%128.54%16.96%12.09%
Forward PE
-----8.497.266.48
No. Analysts
-----10109
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue20252026202720282029
High3.3B3.7B4.2B
Avg2.9B3.1B3.4B
Low2.3B2.6B2.5B

Revenue Growth

Revenue Growth20252026202720282029
High
43.8%
26.3%
32.7%
Avg
28.6%
8.1%
8.6%
Low
2.7%
-12.0%
-19.2%

EPS Forecast

EPS20252026202720282029
High4.696.517.60
Avg4.375.115.73
Low4.004.364.61

EPS Growth

EPS Growth20252026202720282029
High
145.5%
49.0%
48.8%
Avg
128.5%
17.0%
12.1%
Low
109.1%
-0.2%
-9.9%
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.